Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events. Johnson & Johnson, through more than 250 operating companies, manufactures and sells a broad range of products in the healthcare field for the pharmaceutical, consumer, and medical devices and diagnostic markets to most countries of the world. The company is organised on the principles of decentralised management, which gives the company a focus and a sense of ownership in local markets.

J&J's major pharmaceutical growth drivers are Risperdal/Risperdal Consta, Topamax, Concerta and Remicade. However, within our forecast period all of these products bar Remicade are predicted to experience significant sales declines related to patent expiries and generic competition. Other top selling products such as Duragesic, Procrit, Floxin, Levaquin and Aciphex are expected to report reduced sales by 2011.

These threats to sales and growth have placed considerable pressure on J&J's pharmaceutical R&D efforts, although the company has had some recent developmental successes. In 2006, Prezista was launched, becoming J&J's first in-house developed anti-HIV compound. The company is placing increasing importance on virology and Prezista will be J&J's flagship product as it moves into this relatively new area of interest. In addition, 2006 saw the launch of Dacogen for the treatment of myelodysplastic syndromes. This product, alongside Velcade and Doxil, should help expand J&J's profile in the increasingly lucrative field of oncology. The most recent success in R&D was the launch of Invega in January 2007, for the treatment of schizophrenia. J&J's current top-selling product is the Risperdal/Risperdal Consta franchise, also used in the treatment of schizophrenia. Patent protection for Risperdal expires in June 2008, and consequently, the company will hope Invega can become a long-term replacement as Risperdal becomes increasingly less profitable.

Historically, the Consumer segment has been the smallest of J&J's three core businesses. However, in December 2006, the company completed the acquisition of Pfizer's Consumer Healthcare Business for US$17 billion. This purchase should see the Consumer segment compete more effectively with Medical Devices and Diagnostics and Pharmaceuticals. Within Pharmaceuticals, J&J can expect a difficult transition period as older, non-patented products, are replaced with new compounds. The bolstering of the Consumer segment should help overshadow these difficulties in the short-term, and J&J has both in its pipeline, and in its most recent product launches, the assets to achieve growth and strong sales in the medium- to long-term.

This new strategic analysis report Johnson & Johnson: Performance, Products, Pipeline and Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. The report is updated on a quarterly basis. Buyers of the web edition receive quarterly reports for a year. Buyers of the print/pdf editions receive the latest version. All formats are the same price.